Gene Editing System Revamped to Target RNA Aggregates Found in Inherited ALS
Researchers have found a way to break down aggregated RNA molecules that cause diseases such as certain inherited forms of…
Articles by Magdalena Kegel
ALS Patients Are at Higher Risk of Developing Other Neurodegenerative Diseases and Psychiatric Conditions, Study Reports
Amyotrophic lateral sclerosis may have more in common with other neurodegenerative and psychiatric diseases than previously assumed, a study indicates.
U.K. Discovery of How ALS Cells Malfunction Opens Up New Treatment Strategies
RNA molecules that are not supposed to leave the cell nucleus might be responsible for driving neuronal cell death in…
Spine Inflammation Might Explain Why Motor Neurons Die in ALS, Researchers Suggest
Inflammation in the spinal cord, at least in part mediated by a molecule called PGE2, likely contributes to the disease…
Mutant TDP-43 Alone Not Enough to Cause ALS Neurodegeneration, Insect Study Suggests
Mutations in the TDP-43 gene might not be causing the disease changes seen in amyotrophic lateral sclerosis (ALS) on their…
Protein Imbalance May Contribute to ALS, British Researchers Suggest
An imbalance between production and degradation of protein in the central nervous system may contribute to amyotrophic lateral sclerosis (ALS), researchers at…
ALS Therapy Radicava Seen to Uphold Benefits Over Nearly a Year in Extension Trial, Says MT Pharma
Data from the open-label extension trial of Radicava (edaravone) in patients with amyotrophic lateral sclerosis (ALS) demonstrated that the…
Gene Therapy to Strengthen Nerve-Muscle Connection Prevents ALS Progression in Mice
A gene therapy aimed at strengthening the connection between motor neurons and muscle prevented nerve degeneration and increased the life…
FDA Approves Radicava, First New ALS Therapy in 22 Years
The first treatment for amyotrophic lateral sclerosis (ALS) in more than two decades, Radicava (edaravone), has been approved by the U.S. Food…
Biohaven Advances Regulatory Efforts for BHV-0223, a Sublingual Form of ALS Therapy Rilutek
Biohaven Pharmaceuticals is pushing hard for regulatory approval and development of its two investigational drugs for amyotrophic lateral sclerosis (ALS): …